Innokas’ and GlucoSet’s col­lab­o­ra­tion exem­pli­fies an effi­cient prod­uct man­u­fac­tur­ing method

Innokas brings a fresh per­spec­tive on med­ical device devel­op­ment in the col­lab­o­ra­tive project of Glu­coSet and Innokas Design Stu­dios. In this case sto­ry, flex­i­bil­i­ty, trans­paren­cy, and effec­tive com­mu­ni­ca­tion pro­pelled the project to out­stand­ing results. Agile method­ol­o­gy opti­mized the cre­ation of pre­cise patient mon­i­tors for blood glu­cose visu­al­iza­tion. 

Project’s achieve­ments and progress

• The first mile­stone was achieved excep­tion­al­ly quick­ly.
• Method­ol­o­gy: The agile mod­el was applied adept­ly.
• Trans­par­ent com­mu­ni­ca­tion among devel­op­ers, Innokas, and cus­tomer teams.
• Remark­able flex­i­bil­i­ty main­tained, cru­cial for med­ical device con­cepts.
• The project adheres to sched­ule and work esti­ma­tions.
• Pro­to­types demon­strate pos­i­tive results.
• Ongo­ing efforts to enhance man­u­fac­tura­bil­i­ty and pro­ducibil­i­ty.
• Innokas is poised to man­u­fac­ture the device in the future.

High­ly accu­rate glu­cose sen­sors to reduce unnec­es­sary inten­sive care unit deaths

Glu­coSet, a Nor­we­gian med­ical device com­pa­ny, is ded­i­cat­ed to reduc­ing unnec­es­sary deaths in inten­sive care units. They achieve this by devel­op­ing high­ly accu­rate blood glu­cose sen­sors and mon­i­tors. These devices prompt­ly alert med­ical pro­fes­sion­als when patients’ glu­cose lev­els fall below crit­i­cal thresh­olds. Notably, GlucoSet’s min­i­mal­ly inva­sive sen­sor access­es arte­r­i­al catheters with­out dis­rupt­ing exist­ing usage. It’s a promis­ing advance­ment in glu­cose mon­i­tor­ing.

Using the agile approach through­out pro­to­type series devel­op­ment

 Innokas Design Stu­dio has been heav­i­ly involved in the devel­op­ment of the pro­to­type series and indus­tri­al design of the mon­i­tor since the start of the project in 2022. From the begin­ning, apply­ing the agile mod­el has giv­en sig­nif­i­cant ben­e­fits for the whole time­line of the project.     

“This col­lab­o­ra­tion has been very reward­ing for both us and the cus­tomer. Work­ing with an opti­cal device like this has been fan­tas­tic. Projects involv­ing med­ical devices with com­po­nents, such as a spec­trom­e­ter and opti­cal fibers are both chal­leng­ing and grat­i­fy­ing, so they are as ful­fill­ing to work on as they are to com­plete,” said Antti Ylö­nen, Innokas project man­ag­er involved in the project.

“Innokas team of engi­neers, QA, project lead, and man­u­fac­tur­ing pro­vides a stream­lined devel­op­ment process of high qual­i­ty, where they also show they care about Glu­coSets suc­cess and bud­get by active­ly help­ing to mit­i­gate prod­uct and project risks ear­ly. Glu­coSet engi­neered the detailed opto­elec­tron­ic design, and devel­oped and man­u­fac­tured the indwelling glu­cose sen­sor, while Innokas engi­neered the detailed elec­tron­ic hard­ware, mechan­i­cal and indus­tri­al design of the Med­ical Mon­i­tor as part of the Glu­coset CGM sys­tem, and they will man­u­fac­ture the Mon­i­tor in the future,” added Lukas Scher­er, GlucoSet’s CTO.

Con­tact Per­son

Tei­ja Tuli­nen

Mar­ket­ing Spe­cial­ist

Innokas Med­ical Ltd.

teija.tulinen@innokas.eu

Source: Innokas Med­ical